Search

everythinglearnresearchcommunity

for

Search:↓

5-Bromo-3,4-dihydroxybenzaldehyde could potentially help hair growth by activating certain cell pathways and inhibiting others.

Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.

Thymosin β4 helps with healing, inflammation, and organ protection.

Ezetimibe effectively reduces prostate size in cases of benign prostatic hyperplasia.

Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.

Abrocitinib shows promise for treating various skin conditions beyond atopic dermatitis.

Baricitinib is a safe and effective alternative for alopecia areata patients who do not respond to tofacitinib.

Applying a specific inhibitor lightens skin and hair color.

The gene NM_026333 slows down aging by affecting the NCX1 pathway and could be targeted for anti-aging treatments.

Potassium channel openers could help treat cardiovascular diseases and asthma but require better targeting to specific tissues for effective use.

Germacrone from Curcuma aeruginosa may help treat conditions related to male hormones by blocking a specific enzyme.

Baricitinib effectively reduces hair loss in alopecia areata and is well-tolerated.

Activated protein C helps protect mice from long-term radiation damage.

Baricitinib 4 mg is effective and safe for treating severe alopecia areata.

Blocking LFA-1 prevents hair loss in mice.

Pranlukast and mirabegron may work as new diabetes drugs.

PROTAC technology shows promise for cancer treatment but needs more effective E3 ligase recruiters.

Baricitinib treatment helps regrow eyebrow, eyelash, and scalp hair in severe alopecia areata, improving patients' emotional well-being and quality of life.

Selective non-steroidal inhibitors of 5α-reductase type 1 can help treat DHT-related disorders.

The FDA did not approve certain drugs for prostate cancer prevention due to concerns about their effectiveness and potential risks.

Disrupting Acvr1b in mice causes severe hair loss and thicker skin.

Female mice with disrupted 5α-reductase 1 had significant metabolic issues, including stress response problems, insulin resistance, liver fat buildup, and obesity.

Inhibiting AP-1 changes skin tumor types and affects tumor cell identity.

Inhibiting AP-1 changes skin tumor types and affects tumor cell identity.

Dauricine may help treat certain brain cancers by reducing cancer cell growth and promoting cell death.

ACKR2 helps prevent skin scarring and hair loss by controlling inflammation.

Alpha-blockers and 5-alpha reductase inhibitors don't significantly increase dementia risk.